1.
Lancet
; 400(10347): 236, 2022 07 16.
Article
in English
| MEDLINE
| ID: mdl-35843247
2.
Australas J Dermatol
; 62(3): 403-406, 2021 Aug.
Article
in English
| MEDLINE
| ID: mdl-34216144
ABSTRACT
Lichenoid reactions are one of the many cutaneous immune-related adverse events seen with the use of immune checkpoint inhibitors, particularly anti-PD1 inhibitors. We present a rare care of severe lichen planopilaris secondary to pembrolizumab, with progression even after cessation of immunotherapy. It is important to recognise the significant long-term impact of these cutaneous adverse effects on patient's quality of life.
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Immunotherapy/adverse effects , Lichen Planus/chemically induced , Humans , Lichen Planus/prevention & control , Melanoma/diet therapy
3.
BMJ
; 373: n1304, 2021 06 07.
Article
in English
| MEDLINE
| ID: mdl-34099456
Subject(s)
Acneiform Eruptions , COVID-19/prevention & control , Communicable Disease Control/instrumentation , Dermatitis, Contact/diagnosis , Dermatologic Agents , Facial Dermatoses , Masks/adverse effects , N95 Respirators/adverse effects , Rosacea/diagnosis , Skin Care/methods , Acneiform Eruptions/diagnosis , Acneiform Eruptions/etiology , COVID-19/epidemiology , Dermatitis, Contact/etiology , Dermatologic Agents/classification , Dermatologic Agents/pharmacology , Diagnosis, Differential , Facial Dermatoses/diagnosis , Facial Dermatoses/etiology , Facial Dermatoses/physiopathology , Facial Dermatoses/therapy , Humans , Referral and Consultation , Rosacea/physiopathology
4.
Acta Derm Venereol
; 98(4): 477-478, 2018 Apr 16.
Article
in English
| MEDLINE
| ID: mdl-29327062
